NCT00432627View on ClinicalTrials.gov

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Hepatic Impairment
Interventions
DRUG

Deferasirox

one dose of 20 mg/kg/day

Trial Locations (1)

Unknown

Novartis Investigative Site, Kiel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY